Print  |  Close

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Active: Yes
Cancer Type: Multiple Myeloma NCT ID: NCT06106945
Trial Phases: Phase I
Phase II 		Protocol IDs: D7230C00001 (primary)
NCI-2023-10034
2023-508590-89-00
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: AstraZeneca Pharmaceuticals LP
NCI Full Details: http://clinicaltrials.gov/show/NCT06106945

Summary

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose
expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity,
pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.

Objectives

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose
expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity,
pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM. This
study will follow a modular protocol design evaluating AZD0305 as monotherapy and in
combination with other anticancer agents.

The study includes dose escalation and dose expansion phases. This study will enroll
subjects with RRMM who received at least 3 prior lines of treatment including at least
one proteasome inhibitor (PI), one immunomodulator (IMiD), and an anti-CD38 antibody.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.